We are studying the effects of MK-1084, both alone and with cetuximab, in patients with advanced solid tumors that have a KRAS G12C mutation. The goal is to see how well these treatments work and how safe they are.
Health conditions and diseases that the clinical trial is designed to study and treat.
Malignant Neoplasm with KRAS G12C Mutation is a type of cancer where the tumor cells have a specific genetic mutation in the KRAS gene, which can influence the behavior of the cancer and its response to certain treatments.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
